SCHEMBL2066473

SCHEMBL2066473

COCCOc1[c]nccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
MPO P05164 1/20 0.33
PKM P14618 1/20 0.31
CACNA1B Q00975 1/20 0.31
APBA1 Q02410 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
POLB P06746 1/20 0.31
KCNA5 P22460 1/20 0.31
DYRK1A Q13627 2/20 0.30
MEN1 O00255 1/20 0.30
NPC1 O15118 1/20 0.30
LMNA P02545 1/20 0.30
RAB9A P51151 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
MAOA P21397 1/20 0.30
SLC40A1 Q9NP59 1/20 0.30
CA2 P00918 1/20 0.30
KDM1A O60341 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1494518 0.83 NPC1 (0.38) TSHRCHRNB2CHRNA4NPC1LMNA
SCHEMBL1494205 0.81 CYP2D6 (0.42) TSHRNPC1LMNARAB9AKMT2A
SCHEMBL933355 0.80 CHRNB2 (0.51) CHRNB2CHRNA4
SCHEMBL1494545 0.80 LTA4H (0.40) TSHRPOLBNPC1LMNASMN1; SMN2
SCHEMBL4286828 0.79 ALDH1A1 (0.41)
SCHEMBL2068707 0.79
SCHEMBL1494604 0.79 LMNA (0.40) TSHRPOLBMEN1NPC1LMNA
SCHEMBL1494520 0.79 LMNA (0.40) TSHRPOLBMEN1NPC1LMNA
SCHEMBL1494447 0.79 LMNA (0.40) TSHRPOLBMEN1NPC1LMNA
SCHEMBL1494281 0.79 LMNA (0.40) TSHRPOLBMEN1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373318-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2019-06-05 EP claimed
US-8962835-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2015-02-24 US claimed
US-20130310363-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-11-21 US claimed
US-20130231330-A1 IMIDAZOPYRIZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2013-09-05 US claimed
US-8440667-B2 Imidazopyrazine Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2013-05-14 US claimed
EP-2373318-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 EP claimed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 US claimed
WO-2010068258-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 WO claimed
EP-3552607-A2 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2019-10-16 EP disclosed
EP-2373318-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2019-06-05 EP disclosed
US-10093684-B2 Substituted imidazo[1,2-a]pyrazines as Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2018-10-09 US disclosed
US-20170121350-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2017-05-04 US disclosed
US-9567348-B2 Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors GILEAD CONNECTICUT, INC. (US) 2017-02-14 US disclosed
US-20150266902-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2015-09-24 US disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed
WO-2010139747-A1 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2010-12-09 WO disclosed
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS NOVARTIS AG (CH) 2010-12-09 US disclosed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 US disclosed
WO-2010068258-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266902-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 TSHR 2800/4885MPO 814/4885PKM 1590/4885
US-20100311714-A1 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS PRKCA, ABL1, MYLK2 TSHR 3303/4885MPO 1573/4885PKM 451/4885
US-10093684-B2 Substituted imidazo[1,2-a]pyrazines as Syk inhibitors SYK, BTK, ZAP70 TSHR 2502/4885MPO 1295/4885PKM 1186/4885
US-20130310363-A1 IMIDAZOPYRIZINE SYK INHIBITORS SYK, BTK, ZAP70 TSHR 2429/4885MPO 856/4885PKM 898/4885
US-20130231330-A1 IMIDAZOPYRIZINE SYK INHIBITORS SYK, ZAP70, BTK TSHR 3053/4885MPO 762/4885PKM 1039/4885
US-20170121350-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 TSHR 2800/4885MPO 814/4885PKM 1590/4885
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 TSHR 2800/4885MPO 814/4885PKM 1590/4885
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 TSHR 3111/4885MPO 1628/4885PKM 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.